Dopamine plays a role in the regulation of blood pressure by inhibition of sodium transport in renal proximal tubules (RPTs) and relaxation of vascular smooth muscles. Because dopamine receptors can regulate and interact with each other, we studied the interaction of D 1 and D 3 receptors in immortalized RPT cells and mesenteric arteries from Wistar-Kyoto (WKY) and spontaneously hypertensive rats (SHRs), and in human coronary artery smooth muscle cells (CASMCs). In WKY rats, the D 1 -like agonist, fenoldopam, increased D 3 receptor protein in a time-dependent and concentration-dependent manner (EC 50 ϭ4.5ϫ10 Ϫ9 M, t 1/2 ϭ15.8 hours). In SHRs, fenoldopam (10 Ϫ5 M) actually decreased the expression of D 3 receptors. D 1 and D 3 receptor co-immunoprecipitation was increased by fenoldopam (10 Ϫ7 M/24 h) in WKY rats but not in SHRs. The effects of fenoldopam in CASMCs were similar as those in WKY RPT cells (ie, fenoldopam increased D 1 and D 3 receptor proteins). Both D 3 (PD128907, Emaxϭ80%Ϯ6%, pED 50 ϭ5Ϯ0.1) and D 1 -like receptor (fenoldopam, Emaxϭ81%Ϯ8%, pED 50 ϭ5Ϯ0.2, nϭ12) agonists relaxed mesenteric arterial rings. Co-stimulation of D 1 and D 3 receptors led to additive vasorelaxation in WKY rats, but not in SHRs. D 1 and D 3 receptors interact differently in WKY and SHRs. Altered interactions between D 1 and D 3 receptors may play a role in the pathogenesis of genetic hypertension, including human hypertension, because these receptors also interact in human vascular smooth muscle cells. (Hypertension. 2004;43:654-660.) Key Words: receptors Ⅲ dopamine Ⅲ rats Ⅲ hypertension Ⅲ normotension Ⅲ kidney Ⅲ vascular smooth muscle S everal studies have reported that an impaired renal dopaminergic system may contribute to the pathogenesis of hypertension. 1,2 There is increasing evidence for a direct interaction between D 1 -like and D 2 -like receptors in the kidney. In vitro studies have shown that a D 2 -like receptor, in concert with a D 1 -like receptor, synergistically decreases Na ϩ -K ϩ -ATPase, sodium-phosphate co-transporter, and sodium hydrogen exchanger activities in renal proximal tubule and other cells. [3] [4] [5] In rats, during conditions of normal sodium load, and especially with increased sodium load, D 1 -like and D 2 -like receptors interact to increase sodium excretion. 1, 2, 6, 7 The D 1 -like receptor interacting with the specific D 2 -like receptor subtype in renal sodium transport is unknown. The D 1 -like receptor subfamily includes the D 1 and the D 5 receptors, whereas the D 2 , D 3 , and D 4 receptors belong to the D 2 -like receptor subfamily. 1,2 Although D 2 and D 4 receptors are expressed in renal proximal tubules, the major D 2 -like receptor expressed in rat renal proximal tubules is the D 3 receptor. 8,9 D 1 and D 5 receptors are expressed in renal proximal tubules, but the increase in cAMP production secondary to D 1 -like agonist stimulation is primarily a D 1
rather than a D 5 receptor effect. 10 There are no studies on the interaction between D 5 and D 3 receptors, but an interaction between D 1 and D 3 receptors has been reported. In the medulloblastoma TE671 cell line endogenously expressing only D 1 and D 3 dopamine receptors and not the other dopamine receptor subtypes, stimulation of the D 1 receptor increases D 3 receptor mRNA levels. 11 In a previous study, we showed that D 3 and D 1 receptors co-localized in immortalized renal proximal tubule (RPT) cells from normotensive Wistar-Kyoto (WKY) rats and that activation of D 3 dopamine receptors increased D 1 receptor protein expression in these cells. 12 We have found that these immortalized RPT cells have characteristics similar to freshly obtained RPTs and RPT brush-border membranes, at least regarding D 1 -like receptors and responses to G-protein stimulation. [13] [14] [15] The present studies were designed to determine whether D 1 -like receptors regulate D 1 and D 3 receptors and whether the regulation is different in RPT cells from WKY rats and spontaneously hypertensive rats (SHRs). To determine whether D 1 and D 3 receptors also interact in vascular smooth muscle cells, we studied the effect of D 1 and D 3 receptor agonists on the wall tension of rat mesenteric arterial rings from WKY rats and SHRs. We also studied the effect of fenoldopam, a D 1 -like receptor agonist, on D 1 and D 3 receptor expression in human coronary vascular smooth muscle cells (CASMCs). 16 
Methods

Cell Culture
Immortalized RPT cells from WKY rats and SHRs were cultured at 37°C in 95% air/5% CO 2 atmosphere in DMEM/F-12 culture media, as previously described; 17 CASMCs (from Cambrex Bio Science Walkersville, Walkersville, Md) were cultured in smooth muscle growth medium-3. 16 The cells (80% confluence) were extracted in ice-cold lysis buffer (phosphate-buffered saline with 1% NP40, 0.5% sodium deoxycholate, 0.1% SDS, 1 mmol/L EDTA, 1 mmol/L EGTA, 1 mmol/L PMSF, 10 g/mL aprotinin, and 10 g/mL leupeptin), sonicated, kept on ice for 1 hour, and centrifuged at 16 000g for 30 minutes. The supernatants were stored at Ϫ70°C until use for immunoblotting and/or immunoprecipitation.
Immunoblotting
Rat RPT cells and CASMCs were treated with vehicle (dH 2 O), a D 1 -like receptor agonist (fenoldopam), or a D 1 -like receptor antagonist (SCH23390) at the indicated concentrations and times. Immunoblotting was performed as previously reported, except that the transblots were probed with the D 1 (1:800) or the D 3 receptor antibody (1:250). 13, [17] [18] [19] The amount of protein transferred onto the membranes was determined by Ponceau-S staining and immunoblotting for ␣-actin. The receptor densities were normalized by ␣-actin.
Immunoprecipitation
RPT cells were incubated with vehicle or fenoldopam (10 Ϫ7 M or 10 Ϫ6 M) for 30 minutes and 24 hours, as described. 13, 17 The cells were lysed with ice-cold lysis buffer for 1 hour and centrifuged at 16 000g for 30 minutes. Equal amounts of lysates (500 g protein/mL supernatant) were incubated with anti-D 1 receptor antibody (2 L/mL) for 1 hour and protein-G agarose at 4°C for 12 hours. The immunoprecipitates were pelleted and washed four times with lysis buffer. The pellets were suspended in sample buffer, boiled for 10 minutes, and subjected to immunoblotting with the D 3 receptor antibody. To determine the specificity of the bands, pre-immune serum of D 1 receptor antibody (negative control) and D 3 receptor antibody (positive control) were used as immunoprecipitants, instead of the D 1 receptor antibody. The density of the bands was quantified by densitometry, using Quantiscan (Ferguson, MO), as previously reported. 13, [17] [18] [19] 
Mesenteric Artery Study
Male WKY rats and SHRs (Taconic, Germanton, NY) (300 to 350 g, nϭ12 rats/group) anesthetized with sodium pentobarbital (50 mg/kg, intraperitoneal injection), underwent laparotomy, and a portion of intestine and mesentery was cut and kept in ice-cold physiological salt solution (PSS) for isolation of resistance vessels. Four segments of third-generation resistance vessels (250Ϯ20 m) were mounted as ring preparations on four 40-m stainless-steel wires in an isometric Mulvany-Halpern small-vessel myograph (model M610M, J.P. Trading, Science Park, Aarhus, Denmark). 20 In some vessels, the endothelium was removed by pulling a hair along the vessels; successful denudement of the endothelium was confirmed by an absence of relaxation with the addition of acetylcholine. 21 One wire was attached to a force transducer and the other to a micrometer. 21, 22 This arrangement enabled the wall tension to be measured at a predetermined internal circumference. Both the dissection and mounting of the vessels were performed in ice-cold (4°C) PSS.
After mounting, the mesenteric artery ring was equilibrated in PSS for 1 hour at 37°C at a wall tension of 0.1 mN/mm. Based on preliminary data from Ͼ100 vessels, we confirmed that a normalized circumference (L 0 )ϭ0.9 L 100 results in maximal active force development. The vessels were studied at L 0 in all subsequent protocols.
The vessels were stimulated by high-potassium (125 mmol/L) PSS (KPSS). After completion of the activation procedure, the vessels were rinsed three times with fresh PSS and allowed to recover to baseline for 15 minutes. Maximal contraction of the vessel was achieved with KPSS. After reaching a plateau, relaxation was induced with 10 Ϫ5 M of acetylcholine, which tests for endotheliumdependent relaxation. Ligand-induced relaxation was assessed by cumulative addition of drugs to the rings, which were submaximally (50% to 80%) pre-constricted with KPSS. KPSS contracted the mesenteric arteries to the same degree in WKY rats and SHRs (67%Ϯ8% versus 66%Ϯ10%, nϭ12, PϭNS).
To test the action of D 1 and/or D 3 receptors on the mesenteric arterioles, cumulative concentrations (10 Ϫ9 M to 10 Ϫ3 M) of a D 1 -like receptor agonist, fenoldopam, and/or a D 3 receptor agonist, PD128907, were added to the arterial rings pre-constricted by KPSS. To test the interaction between D 1 or D 3 receptor, fenoldopaminduced (10 Ϫ9 to 10 Ϫ3 M) relaxation was studied in vessels preincubated for 30 minutes with PD128907 (10 Ϫ6 M).
Materials
Rabbit anti-rat D 3 receptor antibody (D3R12A) was produced against a synthetic oligopeptide from the amino acid sequence of rat D 3 receptor (amino acids 288 to 306, QPPSPG QTHGGLKRYYSIC) (Alpha Diagnostic International, San Antonio, Tex). Rabbit anti-rat D 1 receptor antibody was produced against a synthetic oligopeptide from the amino acid sequence of rat D 1 receptor (amino acids 299 to 307, GSEETQPFC) (Research Genetics). We have reported the specificity of the D 1 and the D 3 receptor antibodies. 13, [17] [18] [19] Fenoldopam, SCH23390, U99194A, and PD12897 were from Sigma (St. Louis, Mo). Other chemicals for various buffers were of the highest purity available and purchased from Sigma or Gibco. Mouse monoclonal ␣-actin antibody is from Santa Cruz Biotechnology, Inc. (Santa Cruz, Calif).
Statistical Analysis
The data are expressed as meanϮSEM. Comparison within groups was made by repeated measures ANOVA (or paired t test when only 2 groups were compared), and comparison among groups (or t test when only 2 groups were compared) was made by factorial ANOVA with Duncan test. Corresponding periods between 2 different groups were analyzed by independent t test. Fenoldopam and PD128907 sensitivities in blood vessels are expressed as pED 50 , which is the (Ϫlog) concentration of drug required to produce 50% of the maximum response. Relaxation responses to the fenoldopam and PD128907 are expressed as a percentage decrease from the maximum contractile response. A value of PϽ0.05 was considered significant.
Results
Fenoldopam Increased D 3 Receptor Expression in Rat RPT Cells but not in SHRs
Fenoldopam increased D 3 receptor expression in a concentration-dependent and time-dependent manner in RPT cells from WKY rats. The stimulatory effect was evident at 10 Ϫ9 M with a 50% increase (EC 50 ϭ4.5ϫ10 Ϫ9 M) in D 3 receptor expression. The stimulatory effect of fenoldopam (10 Ϫ7 M) was noted as early as 8 hours and maintained for at least 30 hours (t 1/2 ϭ15.8 h). In RPT cells from SHRs, fenoldopam (10 Ϫ7 M) had no effect on D 3 receptor expression (WKY rats: controlϭ1.1Ϯ0.04, fenoldopamϭ1.5Ϯ0.07; SHRs: controlϭ0.8Ϯ0.05, fenoldopamϭ0.7Ϯ0.05; nϭ11/ group) ( Figure 1A ). To determine whether higher concentrations of fenoldopam could have any effect on D 3 receptor expression, SHR cells were treated with varying concentrations of fenoldopam for 24 hours. Consistent with the results from Figure 1A , 10 Ϫ6 to 10 Ϫ10 M fenoldopam had no effect on D 3 receptor protein expression, with 10 Ϫ5 M fenoldopam actually decreasing it ( Figure 1B) .
The specificity of fenoldopam as a D 1 -like receptor agonist was determined by studying the effect of the D 1 -like receptor antagonist, SCH23390 in WKY RPT cells. Consistent with the current and previous results from aortic vascular smooth muscle cells, 23 fenoldopam (10 Ϫ7 M/24 h), increased D 3 receptor expression in WKY RPT cells (controlϭ20Ϯ3 density units [DU], fenoldopamϭ39Ϯ4 DU; nϭ9, PϽ0.05). SCH23390 (10 Ϫ7 M), by itself, had no effect on D 3 receptor expression (23Ϯ2 DU), but reversed the stimulatory effect of fenoldopam on D 3 receptor expression (19Ϯ3 DU) ( Figure 1C ). . For a positive control, anti-D 3 antibodies (1 g/mL) were used as the immunoprecipitant; for a negative control, pre-immune rabbit serum (2 L/mL) was used as the immunoprecipitant instead of the anti-D 1 receptor antibodies, and anti-D 3 receptor antibodies were used for immunoblotting as described. 
D 3 Receptor Co-immunoprecipitated With the D 1 Receptor in Rat RPT Cells
To determine whether there is a physical interaction between the D 1 and the D 3 receptor, D 1 receptors were first immunoprecipitated with anti-D 1 receptor antibodies and then probed with anti-D 3 receptor antibodies. As shown in Figure 2A , the 45-kDa band, representing the co-immunoprecipitated D 3 and D 1 receptors, was increased by a 24-hour treatment of fenoldopam (10 Ϫ7 M) in RPT cells from WKY rats, consistent with our previous report in aortic vascular smooth muscle cells. 23 However, no effect was observed in SHRs (WKY: controlϭ25Ϯ4 DU, fenoldopamϭ40Ϯ3 DU; nϭ7, PϽ0.05; SHRs: controlϭ18Ϯ3 DU, fenoldopamϭ17Ϯ3 DU; nϭ7, PϭNS).
To investigate whether short-term stimulation can affect D 3 /ETB receptor co-immunoprecipitation in WKY cells, and whether higher concentrations of fenoldopam had any effect on this linkage in SHR cells, WKY cells were treated with fenoldopam (10 Ϫ7 M) for 30 minutes and SHR cells were treated with different concentrations of fenoldopam (10 Ϫ7 M and 10 Ϫ6 M) for 30 minutes. Consistent with Figure 2A , fenoldopam (10 Ϫ7 M) also increased the coimmunoprecipitation of D 1 and D 3 receptors at 30 minutes in WKY but minimally in SHR cells. At 10 Ϫ6 M, fenoldopam increased the co-immunoprecipitation of D 1 and D 3 receptors in SHRs to an extent similar to that noted at 10 Ϫ7 M in WKY cells ( Figure 2B ). These data indicated that the sensitivity of SHRs to D 1 -like receptor stimulation was decreased, in agreement with previous studies from our laboratory, using cAMP as the outcome variable. 1, 24 
D 1 Receptors Increased D 3 and D 1 Receptor Protein Expressions in CASMCs
Besides the stimulatory effect of fenoldopam on D 3 receptor, our previous study also showed that fenoldopam increased the expression of its own receptor (D 1 receptor) in WKY RPT cells. 25 D 1 receptor regulation of D 3 and D 1 receptors also occurs in vascular smooth muscle cells; fenoldopam (10 Ϫ7 M/24 h) also increased D 3 receptor protein in CASMCs (D 3 receptor: controlϭ0.9Ϯ0.1, fenoldopamϭ1.4Ϯ0.1, nϭ10; PϽ0.05). The stimulatory effect on D 1 receptors in CASMCs was modest (D 1 receptor: controlϭ1Ϯ0.06, fenoldo-pamϭ1.4Ϯ0.1, nϭ10), compared with the effect in WKY RPT cells. 25 The actions of fenoldopam were exerted at the D 1 receptor because the effects were blocked by a D 1 -like receptor antagonist, SCH23390 (10 Ϫ7 M), which by itself had no effect on D 1 or D 3 receptor protein expression (D 1 receptor: 0.9Ϯ0.1; D 3 receptor: 0.9Ϯ0.1) but reversed the stimulatory effect of fenoldopam on D 1 and D 3 receptor protein expression (D 1 receptor: 0.9Ϯ0.1; D 3 receptor:ϭ0.9Ϯ0.1, nϭ10) ( Figure 3A and B ).
Costimulation of D 1 and D 3 Receptors Had an Additive Vasorelaxant Effect in the Rat Mesenteric Artery From WKY Rats but not From SHRs
We next determined the effect of D 1 and D 3 receptor agonists on the wall tension of rat mesenteric artery rings. In vessels from either WKY rats or SHRs, neither D 1 nor D 3 receptor agonists (fenoldopam 1,2 and PD128907, 26 respectively) had any vasoconstrictor effect. However, in vessels from WKY rats, both agonists relaxed arterial rings pre-constricted with KPSS in a dose-dependent manner (Emax and pED50; Table) ; the vasorelaxant effects were evident at 10 Ϫ6 M ( Figure 4A and B) . These effects were specific, because the D 1 -like receptor antagonist, SCH23390, and D 3 receptor antagonist, U99194A, did not have any effect by themselves but blocked the vasorelaxant effects of their respective agonists. 23 There was an interaction between D 1 and D 3 receptors because fenoldopam-induced vasorelaxation was greater in vessels preincubated with PD128907 than in vehicle-treated vessels (Table, Figure 4C ).
In SHRs, PD12897 dose-dependently relaxed mesenteric arteries pre-constricted by KPSS (Table) ; the effect was similar to that in WKY rats except for a lesser vasorelaxant effect at the two highest concentrations of the drug ( Figure  4A) . In contrast, the mesenteric arteries from SHRs were less sensitive and less reactive than WKY rats to the vasorelaxant effect of fenoldopam (Table and Figure 4B ). Whereas pretreatment of mesenteric arteries with PD128907 enhanced the vasorelaxant effect of fenoldopam in WKY rats ( Figure 4C ), no additional vasorelaxant effect was noted in SHRs (Table, Figure 4D ).
Discussion
We have reported a physical interaction between D 1 and D 3 receptors in rat A10 aortic smooth muscle cells. 23 In A10 and RPT cells from normotensive rats, D 1 receptor stimulation with a D 1 -like agonist, fenoldopam, increases D 1 receptor protein expression. 23, 25 In contrast, in RPT cells from SHRs, fenoldopam has no effect of D 1 receptor expression. 25 The current study extends our previous reports and has several novel observations. First, fenoldopam, via D 1 -like receptors, increases D 3 receptor protein expression in RPT cells from WKY rats. Second, in these cells, D 1 and D 3 receptors co-immunoprecipitate, which is increased by D 1 -like receptor stimulation. Third, the aforementioned effects of D 1 -like receptor stimulation on D 3 receptor protein and D 1 /D 3 receptor co-immunoprecipitation are impaired in SHRs. Fourth, the D 1 -like receptor agonist, fenoldopam, increases D 1 and D 3 receptor protein expressions in human CASMCs. Fifth, activation of either D 1 or D 3 receptor relaxes the mesenteric artery to a greater extent in WKY rats than in SHRs; neither receptor has any vasoconstrictive effect. The simultaneous stimulation of D 1 and D 3 receptors results in an additive vasorelaxation in WKY rats but not in SHRs. D 1 -like and D 2 -like receptors in the kidney have been found to regulate renal sodium handling. The D l -like receptors are always associated with a diuretic and natriuretic action. 1, 2 In contrast, the effect of stimulation of D 2 -like receptors, independent of D l -like receptors, on sodium excretion has produced natriuresis, no effect, or antinatriuresis in different studies. 1 However, in normotensive rats, stimulation of renal D 1 -like and D 2 -like receptors produces a natriuresis that is greater than that observed with D 1 -like receptors alone. 6 In addition, the natriuretic effect of endogenous renal dopamine requires activation of D 1 -like and D 2 -like receptors. 7 Moreover, in concert with a D 1 -like agonist, a D 2 -like agonist acts synergistically to inhibit Na ϩ -K ϩ -ATPase and sodium hydrogen exchanger activity in RPT cells and brain striatal cells . Dose-dependent vasorelaxation by D 1 and D 3 receptors in mesenteric arterial rings from WKY rats and SHRs. Rat mesenteric arterial rings, pre-constricted with KCl (125 mmol/L), were exposed to different concentrations of PD128907 (D 3 receptor agonist; A), fenoldopam (D 1 -like receptor agonist; B), or fenoldopam in mesenteric arterial rings pretreated with PD128907 (10 Ϫ6 M) or vehicle in WKY rats (C) and SHRs (D) (nϭ12/concentration, *PϽ0.01 versus WKY; #PϽ0.01 versus vehicle, Duncan test). and sodium-phosphate cotransport activity in opossum kidney cells. [3] [4] [5] The D 1 -and D 2 -like receptors that interact in renal tubule cells are not known. There are at least two D 1 -like receptors, the D 1 and the D 5 receptor, expressed in the kidney. The D 1 receptor is responsible for most of the increase in cAMP production in renal proximal tubule cells after stimulation with D 1 -like agonist, fenoldopam. Therefore, we have suggested that the D 1 receptor rather than the D 5 receptor is responsible for the natriuretic effect of D 1 -like agonists. 10 The current studies show that the D 1 and the D 3 receptor interact with each other in RPT cells from normotensive rats. Whether the ability of D 1 receptors to stimulate D 3 receptor expression and increase their interaction plays a role in the natriuretic effect of dopamine remains to be determined. We do show that acute (30 minutes) and long-term interactions (24 hours) are impaired in RPT cells from SHRs. An impaired interaction between D 1 -like and D 2 -like receptors in renal proximal tubules has been shown in SHRs, but the dopamine receptor subtypes involved were not determined. 27 A preferential D 3 receptor agonist and two selective D 3 receptor agonists, R(ϩ)-7-hydroxydipropyl-aminotetralin and PD128907, increase sodium excretion in normotensive but not in hypertensive rats. 18, 28, 29 Chronic blockade of D 3 receptors induces hypertension in Dahl salt-resistant rats; 28 mice lacking the D 3 receptor are hypertensive and have a decreased ability to excrete an acute saline load. 30 Several laboratories, including ours, have also shown that renal D 1 receptor function is also impaired in genetic hypertension. 1, 2 It is not known, however, whether the dopaminergic defect in genetic hypertension is primarily caused by the D 1 or D 3 receptor.
Vasorelaxant Effect of the D 1 and the D 3 Agonist in 3rd Generation Mesenteric Arterial Rings of WKY Rats and SHRs
Our studies show that in the maximally vasorelaxed mesenteric artery, a D 1 receptor agonist (fenoldopam) or a D 3 receptor agonist, PD128907, a 120-fold selectivity over the D 2 receptor 26 has no effect on vascular contractility, in agreement with our previous report. 23 The current studies also support our previous report of the vasorelaxant effect of D 1 or D 3 receptors; D 1 -like receptor-induced vasorelaxation is increased with D 3 receptor activation in WKY rats. 23 The vasorelaxant effects of fenoldopam and PD128907 in mesenteric vessels are attenuated in SHRs, although the impairment is greater with fenoldopam than with PD128907. Moreover, in SHRs, unlike the response seen in WKY rats, D 3 receptor stimulation does not enhance the vasodilatory effect of D 1 receptor stimulation. Although fenoldopam is a potent vasodilator of several vascular beds in SHRs and humans with essential hypertension, 31-33 a blunted renal vasodilatory effect has also been reported in SHRs and humans with essential hypertension. 34 -36 We have previously reported that D 1 and D 3 dopamine receptor subtypes physically interact with and regulate each other's expression in A10 aortic vascular smooth muscle cells. 23 The effect of D 1 -like receptors on D 1 and D 3 receptor expressions and their interaction was not studied in mesenteric arterial vascular smooth muscle cells because such cells are not available. We chose to study instead, arterial vascular smooth muscle cells from human coronary arteries. 16 The results are similar to those found in RPT cells and A10 cells from normotensive rats. 23 However, the ability of the D 1 and D 3 receptors to regulate each other's expression in RPT cells from normotensive rats and CASMCs from humans occur only after 2 hours of agonist incubation. Therefore, other mechanisms are probably involved in the enhancement of the vasodilatory effect of D 1 receptors by D 3 receptors, eg, increase in signaling molecules.
The D 1 and D 2 receptors heterologously expressed in Chinese hamster ovary cells (D 2 ϾD 1 ) act synergistically to increase arachidonic acid release. 37 This is an unlikely mechanism for the positive interaction of D 1 and D 3 receptors because dopamine and D 3 receptor agonists actually decrease arachidonic acid release. 38 It is also unlikely that nitric oxide or any endothelium-derived relaxing factor is involved 39 because we have found that removal of endothelial cells does not impair the vasorelaxant effect of D 1 and D 3 receptors. 23 We have suggested that the D 3 receptor-mediated vasorelaxation in vascular smooth muscle cells 23 is caused by stimulation of stimulate K ϩ channels. 40 Under these conditions, the vasorelaxant effects of D 1 -like receptors caused by protein kinase A 1 may be additive to the vasorelaxant effect of D 3 receptors caused by stimulation of K ϩ channels.
In summary, D 1 receptor increases D 1 and D 3 receptor protein expressions in cells from normotensive rat RPTs and human coronary arteries. In addition, D 1 and D 3 receptors relax mesenteric arterial rings and the vasorelaxation are increased by combined D 1 and D 3 receptor stimulation.
Perspectives
The impairment of dopamine receptor-induced vasodilation of mesenteric arterial vessels is greater for D 1 than D 3 receptors in SHRs. It is therefore possible that the dopaminergic defect in genetic hypertension is primarily related to D 1 receptor dysfunction. The cause of the impaired D 1 -like receptors in RPT cells of SHRs is caused by an uncoupling of the D 1 -like receptor by increased activity of G proteincoupled receptor kinases and decreased activity of protein phosphatase 2A. 1 The cause of the impaired D 1 receptor function in vascular smooth cells in SHRs remains to be determined. Whether vascular smooth muscle cells from resistance vessels in SHRs respond to D 1 -like receptor stimulation similarly to RPT cells from SHRs remains to be determined.
